<DOC>
	<DOCNO>NCT00761215</DOCNO>
	<brief_summary>The purpose study determine oral dosage TR-701 use Phase III study patient complicate skin skin structure infection .</brief_summary>
	<brief_title>Phase 2 Study TR-701 Patients With Complicated Skin Skin Structure Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Skin Diseases , Bacterial</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Diagnosed complicate skin skin structure infection least 2 sign symptom Suspected confirm infection due grampositive organism Complicated skin skin structure infection due gramnegative organism Complicated skin skin structure infection require 7 day therapy Uncontrolled diabetes Chronic systemic immunosuppressive therapy AIDS CD4 count &lt; 200 cells/mm3 Uncontrolled hypertension Mild moderate severe renal failure Severe hepatic disease Neutropenia Use antidepressant SSRIs MAOIs 14 day first dose study drug Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Skin</keyword>
	<keyword>Infection</keyword>
	<keyword>Complicated Skin Skin Structure Infection</keyword>
</DOC>